Unité d'hémovigilance. Hôpital Morvan, CHRU de Brest, 5, avenue Foch, 29609 Brest cedex, France.
Unité d'hémovigilance. Hôpital Morvan, CHRU de Brest, 5, avenue Foch, 29609 Brest cedex, France.
Transfus Clin Biol. 2022 Feb;29(1):20-23. doi: 10.1016/j.tracli.2021.09.009. Epub 2021 Oct 9.
The red cell allo-antibodies research is mandatory before transfusion. In France, pretransfusion testing intervals that are prescribed by regulatory and accrediting agencies are commonly 72hours. In the University hospital of Brest, the interval for multi-transfused patients has been 24hours. In this study we aim to analyse these practice and argue the delay.
This is a retrospective study of post-transfusional allo-immunizations from 2015 to 2020. For each patient, the time interval between the last negative research and the allo-immunization was investigated.
189 patients developed allo-antibodies. In 16 patients (8,5%), the interval for allo-immunization was 24hours, 48hours and 72hours in 4, 8 and 4 patients respectively. 12 patients were transfused after the discovery of the allo-antibodies. That means if we have chosen a delay of validity of 72hours, then 9 patients would have been transfused with a negative result.
Checking for allo-antibodies before RBC transfusion with an interval of 24hours (and not 72hours) is pertinent in order to assure an optimal transfusion safety and to limit the risk of hemolytic transfusion reactions. A pretransfusion testing interval of 24hours for multi-transfused patients should be considered.
输血前必须进行红细胞同种抗体研究。在法国，监管和认证机构规定的输血前检测间隔通常为 72 小时。在布雷斯特大学医院，多输血患者的间隔时间为 24 小时。在这项研究中，我们旨在分析这些实践并论证这种延迟的原因。
这是一项回顾性研究，研究对象为 2015 年至 2020 年的输血后同种免疫。对于每个患者，我们都研究了上次阴性研究和同种免疫之间的时间间隔。
189 名患者产生了同种抗体。在 16 名患者（8.5%）中，同种免疫的间隔时间分别为 24 小时、48 小时和 72 小时，分别有 4、8 和 4 名患者。12 名患者在发现同种抗体后接受了输血。这意味着如果我们选择 72 小时的有效期，那么有 9 名患者将接受阴性结果的输血。
为了确保最佳的输血安全性并限制溶血性输血反应的风险，在输血前进行同种抗体检查并将间隔时间缩短至 24 小时（而非 72 小时）是合理的。对于多输血患者，应考虑将输血前检测间隔缩短至 24 小时。
